XOMA Royalty and LAVA Therapeutics amend acquisition agreement terms EMERYVILLE/UTRECHT/PHILADELPHIA - XOMA Royalty Corporation (NASDAQ:XOMA) and LAVA Therapeutics N.V. (NASDAQ:LVTX) announced today they have amended their previously announced share purchase agreement, finalizing the cash component and updating contingent value right (CVR) terms. LAVA, currently valued at $38.91 million in market capitalization, has seen its shares rise nearly 60% year-to-date according to InvestingPro data.